Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Cited by (1,003)

Items 301–400 of 1,003

1. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
   Fernanda Faião‐Flores, Débora Kristina Alves-Fernandes, Paula Comune Pennacchi, Silvana Sandri, Anna Luiza Silva Almeida Vicente, Cristovam Scapulatempo‐Neto, Vinícius de Lima Vazquez, Rui Manuel Reis, Jagat Singh Chauhan, Colin R. Goding et al. · 2016 · Oncogene
2. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer
   Mahadeo A. Sukhai, Kenneth J. Craddock, Mariam Thomas, Aaron Richard Hansen, Tong Zhang, Lillian L. Siu, Philippe Lucien Bedard, Tracy L. Stockley, Suzanne Kamel‐Reid · 2015 · Genetics in Medicine
3. Molecular Pathways: BRAF Induces Bioenergetic Adaptation by Attenuating Oxidative Phosphorylation
   Rizwan Haq, David E. Fisher, Hans R. Widlund · 2014 · Clinical Cancer Research
4. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases
   Yingmei Li, Wenying Pan, Ian David Connolly, Sunil Arani Reddy, Seema Nagpal, Stephen R. Quake, Melanie Hayden Gephart · 2016 · Journal of Neuro-Oncology
5. Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
   Waliul Islam, Jun Qun Fang, Takahisa Imamura, Tomáš Etrych, Vladimír Šubr, Karel Ulbrich, Hiroshi Maeda · 2018 · Molecular Cancer Therapeutics
6. Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
   Patrick Alexander Ott, Omid Hamid, Anna C. Pavlick, Harriet M. Kluger, Kevin B. Kim, Peter D. Boasberg, Ronit Simantov, Elizabeth M. Crowley, Jennifer A. Green, Thomas R. Hawthorne et al. · 2014 · Journal of Clinical Oncology
7. Targeting MAPK pathway in melanoma therapy
   Yabin Cheng, Guohong Zhang, Gang Li · 2013 · Cancer and Metastasis Reviews
8. In vitro and in vivo characterization of pharmaceutical topical nanocarriers containing anticancer drugs for skin cancer treatment
   Gupta, Vandana, Trivedi, Piyush · 2018 · Lipid Nanocarriers for Drug Targeting
9. Sequencing Treatment in BRAF V600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition
   Douglas Buckner Johnson, Eirini Pectasides, Emily Feld, Fei Ye, Shilin Zhao, Romany Anne Nilanthi Johnpulle, Ryan M. Merritt, David F. McDermott, Igor J. Puzanov, Donald P. Lawrence et al. · 2016 · Journal of Immunotherapy
10. BRAF and MEK Inhibitors and Their Toxicities: A Meta-Analysis
    Mattia Garutti, Melissa Bergnach, Jerry Polesel, Lorenza Palmero, Maria Antonietta Pizzichetta, Fabio Puglisi · 2022 · Cancers
11. Erianin suppresses constitutive activation of MAPK signaling pathway by inhibition of CRAF and MEK1/2
    Penglei Wang, Xuechao Jia, Bingbing Lu, Han Huang, Jialin Liu, Xuejiao Liu, Qiong Wu, Yamei Hu, Pan Li, Huifang Wei et al. · 2023 · Signal Transduction and Targeted Therapy
12. Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment
    Vilgelm, Anna E., Johnson, C. Andrew, Prasad, Nripesh, Yang, Jinming, Chen, Sheau-Chiann, Ayers, Gregory D., Pawlikowski, Jeff S., Raman, Dayanidhi, Sosman, Jeffrey A., Kelley, Mark et al. · 2016 · JNCI Journal of the National Cancer Institute
13. Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
    Francesca Del Bufalo, Andrea Carai, Lorenzo Figà-Talamanca, Benedetta Ludovica Pettorini, Conor L. Mallucci, Felice Giangaspero, Manila Antonelli, Manuela Badiali, Loredana Moi, Giuseppe Bianco et al. · 2014 · Journal of Translational Medicine
14. Targeted Therapy for Melanoma
    Deborah J. L. Wong, Antoni Ribas · 2015 · Cancer treatment and research
15. Vemurafenib Sensitivity Skin Reaction after Ipilimumab
    James J. Harding, Melissa P. Pulitzer, Paul B. Chapman · 2012 · New England Journal of Medicine
16. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition
    Helen L. Young, Emily J. Rowling, Mattia Bugatti, Emanuele Giurisato, Nadia Luheshi, Imanol Arozarena, Juan Carlos Acosta, Jivko A. Kamarashev, Dennie Tompers Frederick, Zachary Aaron Cooper et al. · 2017 · The Journal of Experimental Medicine
17. Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies
    S. Jang, Michael B. Atkins · 2013 · Clinical Pharmacology & Therapeutics
18. Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer
    Jennifer Ann Wargo, Zachary Aaron Cooper, Keith T. Flaherty · 2014 · Cancer Discovery
19. MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition
    Teresa Maria Santos Amaral, Tobias W. Sinnberg, Friedegund Elke Meier, Clemens Krepler, Mitchell P. Levesque, Heike Niessner, Claus Garbe · 2017 · European Journal of Cancer
20. miRNA-7-5p inhibits melanoma cell migration and invasion
    Keith Michael Giles, Rikki A. M. Brown, Michael R. Epis, Felicity C. Kalinowski, Peter J. Leedman · 2012 · Biochemical and Biophysical Research Communications
21. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)
    Jun Guo, Shukui Qin, Jun Liang, Tongyu Lin, Lu Si, Xiaohong Chen, Zhihong Chi, Chuanliang Cui, Nan Du, Yun Fan et al. · 2016 · Chinese Clinical Oncology
22. Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin
    Zou, Lili, Ding, Weiping, Zhang, Yuanyuan, Cheng, Shaohui, Li, Fenfen, Ruan, Renquan, Wei, Pengfei, Qiu, Bensheng · 2018 · Biomaterials
23. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma
    Axel Hauschild, James Larkin, Antoni Ribas, Brigitte Dréno, Keith T. Flaherty, Paolo A. Ascierto, Karl D. Lewis, Edward Francis Mckenna, Qian Zhu, Yong Mun et al. · 2018 · JAMA Oncology
24. Targeting autophagy as a potential therapeutic approach for melanoma therapy
    He Liu, Zhaoyue He, Hans‐Uwe Simon · 2013 · Seminars in Cancer Biology
25. Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance
    Antonia L. Pritchard, Nicholas K. Hayward · 2013 · Clinical Cancer Research
26. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials
    Christophe Le Tourneau, Maud T Kamal, Apostolia Maria Tsimberidou, Philippe Lucien Bedard, Gaëlle Pierron, Céline Callens, Étienne Rouleau, Anne Vincent‐Salomon, Nicolas Servant, Marie Alt et al. · 2015 · JNCI Journal of the National Cancer Institute
27. Inhibition of RAF dimers: it takes two to tango
    Frazer A. Cook, Simon J. Cook · 2020 · Biochemical Society Transactions
28. Ethical, Legal, and Counseling Challenges Surrounding the Return of Genetic Results in Oncology
    Martijn P. Lolkema, Christa G. Gadellaa‐van Hooijdonk, Annelien L. Bredenoord, Peter Kapitein, Nancy Roach, Edwin P. J. G. Cuppen, Nine V.A.M. Knoers, Emile E. Voest · 2013 · Journal of Clinical Oncology
29. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells
    Harish Chandra Pal, Ronald D. Baxter, Katherine Marchiony Hunt, Jyoti Agarwal, Craig A. Elmets, Mohammad Athar, Farrukh Afaq · 2015 · Oncotarget
30. Genomics and the History of Precision Oncology
    Deborah B. Doroshow, James H. Doroshow · 2019 · Surgical Oncology Clinics of North America
31. Melanoma classification and management in the era of molecular medicine
    Sarem Rashid, Michael Shaughnessy, Hensin Tsao · 2022 · Dermatologic Clinics
32. Intratumoral Heterogeneity as a Therapy Resistance Mechanism
    Rajasekharan Somasundaram, Jessie Villanueva, Meenhard Herlyn · 2012 · Advances in pharmacology
33. FBXW7 Mutations in Melanoma and a New Therapeutic Paradigm
    Iraz T. Aydin, Rachel Melamed, Sarah J. Adams, Mireia Castillo-Martín, Ahu Demir, Diana Bryk, Georg Brunner, Carlos Cordon‐Cardo, Iman Osman, Raúl Rabadán et al. · 2014 · JNCI Journal of the National Cancer Institute
34. The ERK cascade inhibitors: Towards overcoming resistance
    Galia Maik-Rachline, Rony Seger · 2016 · Drug Resistance Updates
35. Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma
    Anthony J. Olszanski · 2014 · Journal of Managed Care Pharmacy
36. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
    Ryan Joseph Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey Ira Shapiro, Jordi Ahnert Rodon, Michael Millward, Wei Zhang, Ling Gao, Amanda K. Sykes, Melinda D. Willard et al. · 2019 · Molecular Cancer Therapeutics
37. The Role of the Pathologist in the Next-Generation Era of Tumor Molecular Characterization
    Valentina Angerilli, Francesca Galuppini, Fabio Pagni, Nicola Fusco, Umberto Malapelle, Matteo Fassan · 2021 · Diagnostics
38. The Evolving Molecular Genetics of Low-grade Glioma
    Sriram Venneti, Jason T. Huse · 2015 · Advances in Anatomic Pathology
39. New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
    Kaamar Azijli, Ellen Stelloo, Godefridus J. Peters, Alfons J.M. van den Eertwegh · 2014 · PubMed
40. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4
    Celine Marques Pinheiro, Vera Miranda‐Gonçalves, Adhemar Longatto‐Filho, Anna Luiza Silva Almeida Vicente, Gustavo Nóriz Berardinelli, Cristovam Scapulatempo‐Neto, Ricardo Filipe Alves Costa, Cristiano Ribeiro Viana, Rui Manuel Reis, Fátima Baltazar et al. · 2016 · Cell Cycle
41. BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
    Lars Ny, Micaela Hernberg, Marta Nyakas, Jussi Pekka Koivunen, Lars Oddershede, M. Yoon, X. Wang, Patricia Guyot, Jürgen Geisler · 2020 · Acta Oncologica
42. Failures in Phase III: Causes and Consequences
    Boštjan Šeruga, Alberto Ocaña, Eitan Amir, Ian F. Tannock · 2015 · Clinical Cancer Research
43. Cancer treatment according to BRCA1 and BRCA2 mutations
    Kara N. Maxwell, Susan M. Domchek · 2012 · Nature Reviews Clinical Oncology
44. Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
    Marcus C. Ravnan, Mazen S. Matalka · 2012 · Clinical Therapeutics
45. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science
    Fred H. Hochberg, Nadia A. Atai, David D. Gonda, Michael S Hughes, Brolin Mawejje, Leonora Balaj, Robert S Carter · 2014 · Expert Review of Molecular Diagnostics
46. Pathogenesis of cancers derived from thyroid follicular cells
    James A. Fagin, Gnana Prakasam Krishnamoorthy, Iñigo Landa · 2023 · Nature reviews. Cancer
47. BRAF in Melanoma: Current Strategies and Future Directions
    April K.S. Salama, Keith T. Flaherty · 2013 · Clinical Cancer Research
48. HPMA Copolymer-Based Nanomedicines in Controlled Drug Delivery
    Petr Chytil, Libor Kostka, Tomáš Etrych · 2021 · Journal of Personalized Medicine
49. The evolving landscape of tissue‐agnostic therapies in precision oncology
    Vivek Subbiah, Mohamed Alaa Gouda, Bettina Ryll, Howard A. Burris, Razelle Kurzrock · 2024 · CA A Cancer Journal for Clinicians
50. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
    the Cancer and Leukemia Group B, Thomas Frank Gajewski, April K.S. Salama, Donna Niedzwiecki, Jeffrey E. Johnson, Gerald P. Linette, Cynthia J. Bucher, Michelle A. Blaskovich, Saı̈d M. Sebti, Frank G. Haluska · 2012 · Journal of Translational Medicine
51. Therapeutic Advances and Treatment Options in Metastatic Melanoma
    Douglas Buckner Johnson, Jeffrey Alan Sosman · 2015 · JAMA Oncology
52. Novel vitamin D hydroxyderivatives inhibit melanoma growth and show differential effects on normal melanocytes.
    Andrzej T. Slominski, Zorica Janjetović, Tae‐Kang Kim, Adam C. Wright, Laura Grese, Samuel J Riney, Minh N. Nguyen, Robert Charles Tuckey · 2012 · PubMed
53. BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling
    Vin, Harina, Ojeda, Sandra S, Ching, Grace, Leung, Marco L, Chitsazzadeh, Vida, Dwyer, David W, Adelmann, Charles H, Restrepo, Monica, Richards, Kristen N, Stewart, Larissa R et al. · 2013 · eLife
54. Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee
    Channing Judith Paller, Penelope A. Bradbury, S. Percy Ivy, Lesley Seymour, Patricia Mucci LoRusso, Laurence H. Baker, Larry Rubinstein, Erich Huang, Deborah E. Collyar, Susan G. Groshen et al. · 2014 · Clinical Cancer Research
55. Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
    Jason J. Luke, Frank Stephen Hodi · 2013 · The Oncologist
56. Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib
    Rachael M. Anforth, Michael Liu, Bao Nguyen, Pablo Uribe, Richard F. Kefford, Arthur Clements, Georgina Venetia Long, Pablo Fernández‐Peñas · 2013 · Australasian Journal of Dermatology
57. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma
    Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, Thomas C. C. Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean‐Frédéric Blanc, Yuk Ting Ma, Chia Jui Yen, Judit Kocsis et al. · 2018 · Clinical Cancer Research
58. Metastatic melanoma treatment: Combining old and new therapies
    Ryan J. Davey, André van der Westhuizen, Nikola A. Bowden · 2015 · Critical Reviews in Oncology/Hematology
59. Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma
    Matteo Salvatore Carlino, Kavitha Gowrishankar, Catherine A.B. Saunders, Gulietta M. Pupo, Stephanie Snoyman, Xu Dong Zhang, Robyn P.M. Saw, Therese M. Becker, Richard F. Kefford, Georgina Venetia Long et al. · 2013 · Molecular Cancer Therapeutics
60. Targeting drivers of melanoma with synthetic small molecules and phytochemicals
    Leah Ray Strickland, Harish Chandra Pal, Craig A. Elmets, Farrukh Afaq · 2015 · Cancer Letters
61. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers
    Georg Karpel‐Massler, Basil A. J. Horst, Chang Shu, Lily Chau, Takashi Tsujiuchi, Jeffrey N. Bruce, Peter Canoll, Lloyd A. Greene, James M. Angelastro, Markus David Siegelin · 2016 · Clinical Cancer Research
62. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience
    Arjun Khunger, Monica Khunger, Vamsidhar Velcheti · 2018 · Therapeutic Advances in Respiratory Disease
63. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
    Anna A. Marusiak, Zoe C. Edwards, Willy Hugo, Eleanor W. Trotter, María Romina Girotti, Natalie L. Stephenson, Xiangju Kong, Michael G. Gartside, Shameem Fawdar, Andrew Hudson et al. · 2014 · Nature Communications
64. ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
    Shujun Han, Yibo Ren, Wangxiao He, Huadong Liu, Zhe Zhi, Xinliang Zhu, Tie‐Lin Yang, Yu Rong, Bohan Ma, Timothy J. Purwin et al. · 2017 · Nature Communications
65. Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung
    Tsugumasa Kamata, Kuniko Sunami, Akihiko Yoshida, Kouya Shiraishi, Koh Furuta, Yoko Shimada, Hitoshi Katai, Shun-ichi J. WATANABE, Hisao Asamura, Takashi Kohno et al. · 2015 · Journal of Thoracic Oncology
66. Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway
    Chengfang Zhou, Xiang Chen, Weiqi Zeng, Cong Peng, Gang Huang, Xianan Li, Zhengxiao Ouyang, Yi Luo, Xuezheng Xu, Biaobo Xu et al. · 2016 · Oncotarget
67. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF -Mutated Colorectal Cancers
    Zhiyu Tang, Xi Yuan, Rong Du, Shing-Hu Cheung, Guoliang Zhang, Jing Wei, Yuan Zhao, Yingcai Feng, Hao Peng, Yi Zhang et al. · 2015 · Molecular Cancer Therapeutics
68. Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden
    Hanna Eriksson, Johan Lyth, Eva Månsson‐Brahme, Margareta Frohm‐Nilsson, Christian Ingvar, C. Lindholm, Peter L. J. Naredi, Ulrika K. Stierner, Gunnar Wagenius, John M. Carstensen et al. · 2013 · European Journal of Cancer
69. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
    Amanda Lassen, Mohammad S. Atefi, Lídia Robert, Deborah J. L. Wong, Michael Cerniglia, Begonya Comin-Anduix, Antoni Ribas · 2014 · Molecular Cancer
70. BRAF inhibition improves tumor recognition by the immune system
    Marco Donia, Paolo Fagone, Ferdinando Nicoletti, Rikke Sick Andersen, Estrid Vilma Solyom Høgdall, Per thor Straten, Mads Hald Andersen, Inge Marie Svane · 2012 · OncoImmunology
71. B-Raf Inhibition in the Clinic: Present and Future
    Warren C. Fiskus, Nicholas Mitsiades · 2016 · Annual Review of Medicine
72. Dynamics of Chemokine, Cytokine, and Growth Factor Serum Levels in BRAF-Mutant Melanoma Patients during BRAF Inhibitor Treatment
    James S. Wilmott, Lauren Elaine Haydu, Alexander Maxwell Menzies, Trina Lum, Jessica Hyman, John F. Thompson, Peter Hersey, Richard F. Kefford, Richard A. Scolyer, Georgina Venetia Long · 2014 · The Journal of Immunology
73. Melanoma, Version 4.2014
    Daniel G. Coit, John A. Thompson, Robert H.I. Andtbacka, Christopher James Anker, Christopher Keram Bichakjian, William Edgar Carson, Gregory A. Daniels, ADIL I. DAUD, Dominick J. DiMaio, Martin D. Fleming et al. · 2014 · Journal of the National Comprehensive Cancer Network
74. Nanotechnology-empowered strategies in treatment of skin cancer
    Jyoti Chandra, Nazeer Hasan, Nazim Nasir, Shadma Wahab, Punniyakoti Thanikachalam Veeraveedu, Amirhossein Sahebkar, Farhan Jalees Ahmad, Prashant Kesharwani · 2023 · Environmental Research
75. The global challenge for skin health
    Roderick J. Hay, Matthias Augustin, Christopher E.M. Griffiths, Wolfram Sterry, the Board of the International League of Dermatological Societies and the Grand Challenges Consultation groups · 2015 · British Journal of Dermatology
76. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma
    Benamar, Mouadh, Guessous, Fadila, Du, Kangping, Corbett, Patrick, Obeid, Joseph, Gioeli, Daniel, Slingluff, Craig L., Abbas, Tarek · 2016 · eBioMedicine
77. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation
    Hyungsoo Kim, Dennie Tompers Frederick, Mitchell P. Levesque, Zachary Aaron Cooper, Yongmei Feng, Clemens Krepler, Laurence M. Brill, Yardena Samuels, Nicholas K. Hayward, Ally Perlina et al. · 2015 · Cell Reports
78. A personalized view on cancer immunotherapy
    Laura Wayteck, Karine Breckpot, Jo Demeester, Stefaan C. De Smedt, Koen Raemdonck · 2013 · Cancer Letters
79. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
    Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, Christian Posch, Chong Ae Kim, Katia Johnston, Melissa M. Meier, Simona Osella‐Abate, Pietro Quaglino, ADIL I. DAUD et al. · 2014 · Journal of the American Academy of Dermatology
80. Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
    James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa N. Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scolyer, Georgina Venetia Long · 2012 · Molecular Cancer Therapeutics
81. Clinical Trials and Progress in Metastatic Colon Cancer
    Kabir Mody, Tanios Bekaii‐Saab · 2018 · Surgical Oncology Clinics of North America
82. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings
    Kristy Kummerow Broman, Lesly Ann Dossett, James X. Sun, Zeynep Eroglu, Jonathan S. Zager · 2019 · Expert Opinion on Drug Safety
83. Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies
    Allison S. Dobry, Cheryl K. Zogg, Frank Stephen Hodi, Timothy Richard Smith, Patrick Alexander Ott, Julian Bryan Iorgulescu · 2018 · Cancer Immunology Immunotherapy
84. RNA–DNA fibers and polygons with controlled immunorecognition activate RNAi, FRET and transcriptional regulation of NF-κB in human cells
    Weina Ke, Enping Hong, Renata de Freitas Saito, María Cristina Rangel, Jian Wang, Mathias Viard, Melina Richardson, Emil F. Khisamutdinov, Martin Panigaj, Nikolay V. Dokholyan et al. · 2018 · Nucleic Acids Research
85. The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition
    Matthew M. K. Chan, Lauren Elaine Haydu, Alexander Maxwell Menzies, Mary Azer, Oliver Klein, Megan Kate Lyle, Arthur Clements, Alexander David Guminski, Richard F. Kefford, Georgina Venetia Long · 2014 · Cancer
86. Emerging insights into resistance to BRAF inhibitors in melanoma
    Amanda Dawn Bucheit, Michael A. Davies · 2013 · Biochemical Pharmacology
87. Resistance to RAF Inhibitors Revisited
    Edward J. Hartsough, Yongping Shao, Andrew E. Aplin · 2013 · Journal of Investigative Dermatology
88. Genetic Alterations and Personalized Medicine in Melanoma: Progress and Future Prospects
    Klaus Griewank, Richard A. Scolyer, John F. Thompson, Keith T. Flaherty, Dirk Schadendorf, Rajmohan Murali · 2014 · JNCI Journal of the National Cancer Institute
89. Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions
    Berglind Osk Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, Henrik Jespersen, Jan Mattsson, Lisa M. Nilsson, Katarina Truvé, Marcela Dávila López, Peter L. J. Naredi, Ola Nilsson et al. · 2014 · Oncotarget
90. The Future of Nuclear Medicine as an Independent Specialty
    Johannes G. Czernin, Ida Sonni, Aria A. Razmaria, Jérémie Calais · 2019 · Journal of Nuclear Medicine
91. Long-term outcome in BRAFV600E melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression
    Igor J. Puzanov, Ravi K. Amaravadi, Grant A. McArthur, Keith T. Flaherty, Paul B. Chapman, Jeffrey Alan Sosman, Antoni Ribas, Mark J. Shackleton, Patrick Hwu, Bartosz Chmielowski et al. · 2015 · European Journal of Cancer
92. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma
    Paola Queirolo, Virginia Picasso, Francesco Spagnolo · 2015 · Cancer Treatment Reviews
93. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
    Erika von Euw, Mohammad S. Atefi, Narsis Attar, Connie Chu, Sybil Zachariah, Barry L. Burgess, Stephen Mok, Charles Ng, Deborah J. L. Wong, Bartosz Chmielowski et al. · 2012 · Molecular Cancer
94. Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model
    Kei Kawaguchi, Takashi Murakami, Bartosz Chmielowski, Kentaro Igarashi, Tasuku Kiyuna, Michiaki Unno, Scott D. Nelson, Tara A. Russell, Sarah Dry, Yunfeng Li et al. · 2016 · Oncotarget
95. High concordance rate of KRAS/BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases
    Kenji Fujiyoshi, Gou Yamamoto, Akemi Takahashi, Yoshiko Arai, Mina Yamada, Miho Kakuta, Kensei Yamaguchi, Yoshito Akagi, Yoji Nishimura, Hirohiko Sakamoto et al. · 2016 · Oncology Reports
96. Sensitivity of plasma BRAFmutant and NRASmutant cell‐free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non‐RECIST disease progression
    Gregory A. Chang, Jyothirmayee S. Tadepalli, Yongzhao Shao, Yilong Zhang, Sarah Ann Weiss, Eric Michael Robinson, Cindy Spittle, Manohar R. Furtado, Dawne N. Shelton, George A. Karlin-Neumann et al. · 2015 · Molecular Oncology
97. BRAF and MEK inhibition in melanoma
    Lesly Ann Dossett, Ragini Reiney Kudchadkar, Jonathan S. Zager · 2015 · Expert Opinion on Drug Safety
98. Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib
    Rebecca Horbert, Boris Pinchuk, Paul Davies, Dario R. Alessi, Christian Peifer · 2015 · ACS Chemical Biology
99. Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort
    Julian Bryan Iorgulescu, Maya Harary, Cheryl K. Zogg, Keith Lloyd Ligon, David A. Reardon, Frank Stephen Hodi, Ayal Aaron Aizer, Timothy Richard Smith · 2018 · Cancer Immunology Research
100. Targeting the Proline–Glutamine–Asparagine–Arginine Metabolic Axis in Amino Acid Starvation Cancer Therapy
     Macus Tien Kuo, Helen Chen, Lynn G. Feun, Niramol Savaraj · 2021 · Pharmaceuticals